PDE-4 Topical Formulations with Phosphate Ester Surfactants

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Phosphodiesterase-4 (PDE-4) inhibitors like roflumilast cause significant gastrointestinal side effects due to a sharp spike in plasma concentration (Cmax) upon oral administration, leading to reduced patient compliance.

Innovation Solution

Incorporating one or more phosphate ester surfactants into topical formulations of PDE-4 inhibitors, such as roflumilast, alters the pharmacokinetic profile to reduce the Cmax spike while maintaining a high Area Under the Curve (AUC) for systemic efficacy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If PDE-4 inhibitors are administered orally to achieve systemic efficacy, then therapeutic effect is improved, but gastrointestinal side effects worsen due to sharp Cmax spike

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidgastrointestinal side effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies preliminary action by using a sustained-release formulation that pre-controls the drug release rate before administration. The formulation is designed to release the PDE-4 inhibitor gradually over time, preventing the sharp Cmax spike that causes gastrointestinal side effects while maintaining therapeutic efficacy throughout the dosing interval.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent changes the pharmacokinetic parameters of the drug by formulating it as a sustained-release preparation. This modifies the concentration-time profile, reducing peak concentration (Cmax) and extending the duration of action, thereby maintaining therapeutic levels while minimizing gastrointestinal side effects.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If oral dosage is used to achieve systemic exposure, then therapeutic effect is improved, but patient compliance worsens due to side effects

Engineering Contradiction:

Improvetherapeutic effectVSAvoidpatient compliance

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The sustained-release formulation is designed in advance to release the drug at a controlled rate, preventing side effects before they occur. This preliminary design feature addresses compliance issues by ensuring that therapeutic benefits are maintained without the gastrointestinal side effects that would otherwise cause patients to discontinue treatment.

Inventive Principle:

Principle #10Preliminary action

3Speed

If rapid absorption is achieved through oral administration, then onset of action is improved, but Cmax spike increases causing side effects

Engineering Contradiction:

Improveonset of actionVSAvoidCmax spike

Core Design Contradiction:

SpeedVSObject-generated harmful factors

Solution Approach 1:

The patent changes the absorption parameters by using a sustained-release formulation that controls the rate of drug release. Instead of rapid absorption leading to high Cmax, the formulation achieves a gradual increase in plasma concentration that maintains therapeutic levels while avoiding the harmful Cmax spike.

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS12390453B2Method for reducing side effects from administration of phosphodiesterase-4 inhibitors

Publication Date: 2025.08.19 ARCUTIS BIOTHERAPEUTICS INC

AI summary

A method for altering the PK profile of a pharmaceutical formulation containing a PDE-4 inhibitor, such as roflumilast, to reduce the spike in Cmax. The spike in Cmax is reduced by topically administering the PDE-4 inhibitor in combination with one or more phosphate ester surfactants. Reducing the spike in Cmax will reduce gastrointestinal side effects and result in better patient compliance.